Analysts Anticipate CorMedix Inc (NASDAQ:CRMD) Will Post Earnings of -$0.25 Per Share

Wall Street analysts predict that CorMedix Inc (NASDAQ:CRMD) will announce ($0.25) earnings per share for the current fiscal quarter, Zacks reports. Two analysts have provided estimates for CorMedix’s earnings. CorMedix posted earnings of ($0.55) per share during the same quarter last year, which suggests a positive year-over-year growth rate of 54.5%. The firm is scheduled to issue its next earnings report on Wednesday, November 13th.

According to Zacks, analysts expect that CorMedix will report full year earnings of ($0.78) per share for the current year. For the next financial year, analysts forecast that the company will post earnings of ($1.64) per share, with EPS estimates ranging from ($2.26) to ($1.01). Zacks’ earnings per share averages are a mean average based on a survey of research analysts that follow CorMedix.

CorMedix (NASDAQ:CRMD) last announced its earnings results on Tuesday, August 13th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.22) by ($0.02). The company had revenue of $0.04 million during the quarter, compared to analyst estimates of $0.13 million.

CorMedix stock traded down $0.24 during midday trading on Wednesday, reaching $6.02. The stock had a trading volume of 5,805 shares, compared to its average volume of 447,325. The firm’s fifty day simple moving average is $7.76 and its 200-day simple moving average is $7.82. CorMedix has a 1-year low of $4.20 and a 1-year high of $13.70.

About CorMedix

CorMedix, Inc, a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. Its primary focus is on the development of its lead product candidate, Neutrolin, an anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as dialysis, critical/intensive care, and oncology.

Read More: 52-Week High/Low Prices For Stock Selection

Get a free copy of the Zacks research report on CorMedix (CRMD)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for CorMedix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CorMedix and related companies with's FREE daily email newsletter.